|
1
|
Nowakowska M, Matysiak-Burzyńska Z,
Kowalska K, Płuciennik E, Domińska K and Piastowska-Ciesielska AW:
Angiotensin II promotes endometrial cancer cell survival. Oncol
Rep. 36:1101–1110. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mizunuma M, Yokoyama Y, Futagami M, Horie
K, Watanabe J and Mizunuma H: FOXP1 forkhead transcription factor
is associated with the pathogenesis of endometrial cancer. Heliyon.
2:e001162016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ito F, Furukawa N and Nakai T: Evaluation
of TOP2A as a predictive marker for endometrial cancer with
taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer.
26:325–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Supernat A, Łapińska-Szumczyk S, Majewska
H, Gulczyński J, Biernat W, Wydra D and Zaczek AJ: A multimarker
qPCR platform for the characterisation of endometrial cancer. Oncol
Rep. 31:1003–1013. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Torres A, Torres K, Pesci A, Ceccaroni M,
Paszkowski T, Cassandrini P, Zamboni G and Maciejewski R:
Diagnostic and prognostic significance of miRNA signatures in
tissues and plasma of endometrioid endometrial carcinoma patients.
Int J Cancer. 132:1633–1645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM,
Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, et al:
Uterine neoplasms. version 1.2017. 2016 National Comprehensive
Cancer Network Inc.; 2017
|
|
7
|
Kaloglu S, Guraslan H, Tekirdag AI,
Dagdeviren H and Kaya C: Relation of preoperative thrombocytosis
between tumor stage and grade in patients with endometrial cancer.
Eurasian J Med. 46:164–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial
cancer: Diagnosis, treatment and follow-up. Radiother Oncol.
117:559–581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mou T, Zhu D, Wei X, Li T, Zheng D, Pu J,
Guo Z and Wu Z: Identification and interaction analysis of key
genes and microRNAs in hepatocellular carcinoma by bioinformatics
analysis. World J Surg Oncol. 15:632017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bastos HP, Tavares B, Pesquita C, Faria D
and Couto FM: Application of gene ontology to gene identification.
Methods Mol Biol. 760:141–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44:D457–D462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:(Database Issue). D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su G, Morris JH, Demchak B and Bader GD:
Biological network exploration with Cytoscape 3. Curr Protoc
Bioinformatics. 47:8.13.1. 242014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Supernat A, Lapińska-Szumczyk S, Majewska
H, Gulczyński J, Biernat W, Wydra D and Zaczek AJ: Tumor
heterogeneity at protein level as an independent prognostic factor
in endometrial cancer. Transl Oncol. 7:613–619. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pei YF, Yin XM and Liu XQ: TOP2A induces
malignant character of pancreatic cancer through activating
β-catenin signaling pathway. Biochim Biophys Acta. 1864:197–207.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Labbé DP, Sweeney CJ, Brown M, Galbo P,
Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, et
al: TOP2A and EZH2 provide early detection of an aggressive
prostate cancer subgroup. Clin Cancer Res. 23:7072–7083. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng H, Li X, Chen C, Chen J, Sun J, Sun
S, Jin L, Li J, Sun S and Wu X: Quantum dot-based immunofluorescent
imaging and quantitative detection of TOP2A and prognostic value in
triple-negative breast cancer. Int J Nanomedicine. 11:5519–5529.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pei YY, Li GC, Ran J and Wei FX: Kinesin
family member 11 contributes to the progression and prognosis of
human breast cancer. Oncol Lett. 14:6618–6626. 2017.PubMed/NCBI
|
|
20
|
Imai T, Oue N, Sentani K, Sakamoto N,
Uraoka N, Egi H, Hinoi T, Ohdan H, Yoshida K and Yasui W: KIF11 is
required for spheroid formation by oesophageal and colorectal
cancer cells. Anticancer Res. 37:47–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Venere M, Horbinski C, Crish JF, Jin X,
Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, et al: The
mitotic kinesin KIF11 is a driver of invasion, proliferation, and
self-renewal in glioblastoma. Sci Transl Med. 7:304ra1432015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schneider MA, Christopoulos P, Muley T,
Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller
NS, Theis F and Meister M: AURKA, DLGAP5, TPX2, KIF11 and CKAP5:
Five specific mitosis-associated genes correlate with poor
prognosis for non-small cell lung cancer patients. Int J Oncol.
50:365–372. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Daigo K, Takano A, Thang PM, Yoshitake Y,
Shinohara M, Tohnai I, Murakami Y, Maegawa J and Daigo Y:
Characterization of KIF11 as a novel prognostic biomarker and
therapeutic target for oral cancer. Int J Oncol. 52:155–165.
2018.PubMed/NCBI
|
|
24
|
Jiang M, Zhuang H, Xia R, Gan L, Wu Y, Ma
J, Sun Y and Zhuang Z: KIF11 is required for proliferation and
self-renewal of docetaxel resistant triple negative breast cancer
cells. Oncotarget. 8:92106–92118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han JY, Han YK, Park GY, Kim SD, Kim JS,
Jo WS and Lee CG: Bub1 is required for maintaining cancer stem
cells in breast cancer cell lines. Sci Rep. 5:159932015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Davidson B, Nymoen DA, Elgaaen BV, Staff
AC, Tropé CG, Kaern J, Reich R and Falkenthal TE: BUB1 mRNA is
significantly co-expressed with AURKA and AURKB mRNA in
advanced-stage ovarian serous carcinoma. Virchows Arch.
464:701–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nyati S, Schinske-Sebolt K, Pitchiaya S,
Chekhovskiy K, Chator A, Chaudhry N, Dosch J, Van Dort ME,
Varambally S, Kumar-Sinha C, et al: The kinase activity of the
Ser/Thr kinase BUB1 promotes TGF-beta signaling. Sci Signal.
8:ra12015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li L, Xu DB, Zhao XL and Hao TY:
Combination analysis of Bub1 and Mad2 expression in endometrial
cancer: Act as a prognostic factor in endometrial cancer. Arch
Gynecol Obstet. 288:155–165. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Yao Y, Zhang L, Li X, Wang Y, Zhao
L, Wang J, Wang G, Shen D, Wei L and Zhao J: cDNA microarray
analysis and immunohistochemistry reveal a distinct molecular
phenotype in serous endometrial cancer compared to endometrioid
endometrial cancer. Exp Mol Pathol. 91:373–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu D, Xu W, Ding X, Yang Y, Su B and Fei
K: Polymorphisms of CCNB1 associated with the clinical outcomes of
platinum-based chemotherapy in Chinese NSCLC patients. J Cancer.
8:3785–3794. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fang Y, Yu H, Liang X, Xu J and Cai X:
Chk1-induced CCNB1 overexpression promotes cell proliferation and
tumor growth in human colorectal cancer. Cancer Biol Ther.
15:1268–1279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim SK, Roh YG, Park K, Kang TH, Kim WJ,
Lee JS, Leem SH and Chu IS: Expression signature defined by
FOXM1-CCNB1 activation predicts disease recurrence in
non-muscle-invasive bladder cancer. Clin Cancer Res. 20:3233–3243.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai H, Xiang YB, Qu S, Long J, Cai Q, Gao
J, Zheng W and Shu XO: Association of genetic polymorphisms in
cell-cycle control genes and susceptibility to endometrial cancer
among Chinese women. Am J Epidemiol. 173:1263–1271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kavlashvili T, Jia Y, Dai D, Meng X, Thiel
KW, Leslie KK and Yang S: Inverse relationship between progesterone
receptor and Myc in endometrial cancer. PLoS One. 11:e01489122016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Noske A, Brandt S, Valtcheva N, Wagner U,
Zhong Q, Bellini E, Fink D, Obermann EC, Moch H and Wild PJ:
Detection of CCNE1/URI (19q12) amplification by in situ
hybridisation is common in high grade and type II endometrial
cancer. Oncotarget. 8:14794–14805. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakayama N, Nakayama K, Shamima Y,
Ishikawa M, Katagiri A, Iida K and Miyazaki K: Gene amplification
CCNE1 is related to poor survival and potential therapeutic target
in ovarian cancer. Cancer. 116:2621–2634. 2010.PubMed/NCBI
|
|
37
|
Yao Y, Luo J, Sun Q, Xu T, Sun S, Chen M,
Lin X, Qian Q, Zhang Y, Cao L, et al: HOXC13 promotes proliferation
of lung adenocarcinoma via modulation of CCND1 and CCNE1. Am J
Cancer Res. 7:1820–1834. 2017.PubMed/NCBI
|
|
38
|
Shi R, Sun J, Sun Q, Zhang Q, Xia W, Dong
G, Wang A, Jiang F and Xu L: Upregulation of FAM83D promotes
malignant phenotypes of lung adenocarcinoma by regulating cell
cycle. Am J Cancer Res. 6:2587–2598. 2016.PubMed/NCBI
|
|
39
|
Krivega MV, Geens M, Heindryckx B,
Santos-Ribeiro S, Tournaye H and Van de Velde H: Cyclin E1 plays a
key role in balancing between totipotency and differentiation in
human embryonic cells. Mol Hum Reprod. 21:942–956. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xiao J, He B, Zou Y, Chen X, Lu X, Xie M,
Li W, He S, You S and Chen Q: Prognostic value of decreased FOXP1
protein expression in various tumors: A systematic review and
meta-analysis. Sci Rep. 6:304372016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hu Z, Zhu L, Tan M, Cai M, Deng L, Yu G,
Liu D, Liu J and Lin B: The expression and correlation between the
transcription factor FOXP1 and estrogen receptors in epithelial
ovarian cancer. Biochimie. 109:42–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cui R, Guan Y, Sun C, Chen L, Bao Y, Li G,
Qiu B, Meng X, Pang C and Wang Y: A tumor-suppressive microRNA,
miR-504, inhibits cell proliferation and promotes apoptosis by
targeting FOXP1 in human glioma. Cancer Lett. 374:1–11. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Giatromanolaki A, Koukourakis MI, Sivridis
E, Gatter KC, Harris AL and Banham AH: Loss of expression and
nuclear/cytoplasmic localization of the FOXP1 forkhead
transcription factor are common events in early endometrial cancer:
Relationship with estrogen receptors and HIF-1alpha expression. Mod
Pathol. 19:9–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Han L, Wang W, Ding W and Zhang L: MiR-9
is involved in TGF-β1-induced lung cancer cell invasion and
adhesion by targeting SOX7. J Cell Mol Med. 21:2000–2008. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang H, Wu Q, Zhang Y, Zhang HN, Wang YB
and Wang W: TGF-β1-induced epithelial-mesenchymal transition in
lung cancer cells involves upregulation of miR-9 and downregulation
of its target, E-cadherin. Cell Mol Biol Lett. 22:222017.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu DZ, Chang B, Li XD, Zhang QH and Zou
YH: MicroRNA-9 promotes the proliferation, migration, and invasion
of breast cancer cells via down-regulating FOXO1. Clin Transl
Oncol. 19:1133–1140. 2017. View Article : Google Scholar : PubMed/NCBI
|
